Quintiles (Q) PT Raised to $81 at Jefferies; Reiterates Hold

Quintiles (Q) PT Raised to $93 at Mizuho Securities

May 4, 2017 4:58 AM EDT

Mizuho Securities raised its price target on Quintiles (NYSE: Q) to $93.00 (from $90.00) while maintaining a Buy rating.

Analyst Ann Hynes believes the stock price weakness is largely due to book-to-bill concerns as investors digest the sequential declines. Hynes believes these concerns are... More

U.S. prescription drug spending as high as $610 billion by 2021: report

May 4, 2017 12:45 AM EDT

By Bill Berkrot

(Reuters) - Spending on prescription medicines in the United States will increase 4-7 percent through 2021, reaching $580 billion to $610 billion, according to a report released by QuintilesIMS Holding (NYSE: Q) on Thursday that lowered its prior long-term forecast.

QuintilesIMS, which compiles data for the pharmaceutical industry, had previously forecast average spending growth of 6-9 percent through 2021. It reduced its projections due to fewer new medicines approved in 2016 than prior years and as drugmakers face increasing pricing pressure and competition.

Taking likely manufacturer discounts and rebates into account,... More

Quintiles (Q) PT Raised to $88.50 at Evercore ISI

May 3, 2017 12:13 PM EDT

Evercore ISI raised its price target on Quintiles (NYSE: Q) to $88.50 (from $84.00) while maintaining an In Line rating following.

Ross Muken is not surprised at today's weakness as the company continues to polorize investors as it transforms business model and reposition the company to... More

QuintilesIMS (Q) Tops Q1 EPS by 5c; Raises FY17 Adj. EPS Guidance

May 3, 2017 7:03 AM EDT

QuintilesIMS (NYSE: Q) reported Q1 EPS of $1.01, $0.05 better than the analyst estimate of $0.96. Revenue for the quarter came in at $1.91 billion versus the consensus estimate of $1.91 billion.

GUIDANCE:

QuintilesIMS sees FY2017 EPS of $4.45-$4.60, versus the consensus of $4.48. QuintilesIMS sees FY2017... More